Ocaña A - Search Results

1

Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy.

Templeton AJ, Rodríguez-Lescure Á, Ruíz A, Alba E, Calvo L, Ruíz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Ramos M, Gracia-Marco JM, Lluch A, Álvarez I, Casas MI, Sánchez-Aragó M, Caballero R, Carrasco E, Amir E, Martin M, Ocaña A; GEICAM 9906 Study Investigators. Templeton AJ, et al. Among authors: ocana a. Clin Transl Oncol. 2018 Dec;20(12):1548-1556. doi: 10.1007/s12094-018-1885-5. Epub 2018 May 15. Clin Transl Oncol. 2018. PMID: 29766456

2

Integrating trastuzumab in the treatment of breast cancer. Current status and future trends.

Ocaña A, Rodríguez CA, Cruz JJ. Ocaña A, et al. Clin Transl Oncol. 2005 Apr;7(3):99-100. doi: 10.1007/BF02708741. Clin Transl Oncol. 2005. PMID: 15899216 Review. No abstract available.

3

Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance.

Ocaña A, Cruz JJ, Pandiella A. Ocaña A, et al. Am J Clin Oncol. 2006 Feb;29(1):90-5. doi: 10.1097/01.coc.0000190274.00570.0a. Am J Clin Oncol. 2006. PMID: 16462510 Review.

4

Case 3. Upper limb lymphangiosarcoma following breast cancer therapy.

Ocaña A, Delgado C, Rodríguez CA, Bellido L, Izquierdo N, Martín R, Cruz JJ. Ocaña A, et al. J Clin Oncol. 2006 Mar 20;24(9):1477-8. doi: 10.1200/JCO.2005.01.8473. J Clin Oncol. 2006. PMID: 16549844 No abstract available.

5

Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer.

Ocaña A, Hortobagyi GN, Esteva FJ. Ocaña A, et al. Clin Breast Cancer. 2006 Feb;6(6):495-504. doi: 10.3816/CBC.2006.n.002. Clin Breast Cancer. 2006. PMID: 16595032 Review.

6

Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer.

de Alava E, Ocaña A, Abad M, Montero JC, Esparís-Ogando A, Rodríguez CA, Otero AP, Hernández T, Cruz JJ, Pandiella A. de Alava E, et al. Among authors: ocana a. J Clin Oncol. 2007 Jul 1;25(19):2656-63. doi: 10.1200/JCO.2006.08.6850. J Clin Oncol. 2007. PMID: 17602072

7

Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options.

Ocaña A, Pandiella A. Ocaña A, et al. Clin Cancer Res. 2008 Feb 15;14(4):961-70. doi: 10.1158/1078-0432.CCR-07-1630. Clin Cancer Res. 2008. PMID: 18281527 Review.

8

An update on the biology of cancer stem cells in breast cancer.

García Bueno JM, Ocaña A, Castro-García P, Gil Gas C, Sánchez-Sánchez F, Poblet E, Serrano R, Calero R, Ramírez-Castillejo C. García Bueno JM, et al. Among authors: ocana a. Clin Transl Oncol. 2008 Dec;10(12):786-93. doi: 10.1007/s12094-008-0291-9. Clin Transl Oncol. 2008. PMID: 19068449 Review.

9

Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.

Ocaña A, Amir E. Ocaña A, et al. Cancer Treat Rev. 2009 Dec;35(8):685-91. doi: 10.1016/j.ctrv.2009.08.001. Epub 2009 Sep 4. Cancer Treat Rev. 2009. PMID: 19733440 Review.

10

Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.

Amir E, Ocaña A, Seruga B, Freedman O, Clemons M. Amir E, et al. Among authors: ocana a. Cancer Treat Rev. 2010 Aug;36(5):410-5. doi: 10.1016/j.ctrv.2009.12.012. Epub 2010 Jan 25. Cancer Treat Rev. 2010. PMID: 20100635 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

286 results

Search Page

Filters